Skip to main content
. 2019 Jun 20;23(8):5672–5678. doi: 10.1111/jcmm.14475

Figure 2.

Figure 2

MAGE‐C1/CT7 change in different response groups. MAGE‐C1/CT7 expression levels correlate with the clinical course of AL amyloidosis. (A), The expression levels of MAGE‐C1/CT7 decreased in 15 patients whose clinical efficacy was complete remission (CR). (B), The expression levels of MAGE‐C1/CT7 decreased in 7 out 9 patients whose clinical efficacy was partial remission (PR). (C), The expression levels of MAGE‐C1/CT7 increased or stable in 3 out 4 patients whose clinical efficacy was NR (no remission)/PD (progression disease).